Marksans Pharma Ltd.

NSE: MARKSANS | BSE: 524404 | ISIN: INE750C01026 | Industry: Pharmaceuticals
| Mid-range Performer

224.86
-1.14%
Karvy
The company reported revenue growth of 8.9% for Q4FY15 over Q4FY14 and annual revenue reported a growth of 26.4% for FY15 over FY14.The company's Europe & UK segment reported growth of 25.7% while the US & North America reported growth of 65.3%. The improved product mix is reflected in operating margins which to 23.2% from 19.2% in FY14
Marksans Pharma Ltd. is trading below all available SMAs
More from Marksans Pharma Ltd.
Recommended